Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter Observational Registry Evaluating the Clinical Impact of the Blood-Based Biomarker Test, PancreaSure, for Early-Stage Pancreatic Ductal Adenocarcinoma (PDAC) Detection in High-Risk Surveillance Program

NCT07805681 is registered in ClinicalTrials.gov with Immunovia, Inc. as lead sponsor.

NCT NCT07805681
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07805681 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter Observational Registry Evaluating the Clinical Impact of the Blood-Based Biomarker Test, PancreaSure, for Early-Stage Pancreatic Ductal Adenocarcinoma (PDAC) Detection in High-Risk Surveillance Program
Lead sponsor
Immunovia, Inc.
Phase
Observational
Overall status
Not yet recruiting
Start date
September 30, 2026
Completion date
April 30, 2029
Enrollment
400 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

cancer diagnosis, pancreatic cancer stage i, pancreatic cancer stage ii, pdac - pancreatic ductal adenocarcinoma